Saxagliptin: a new option for the management of type 2 diabetes

Incretin‐based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase‐IV (DPP‐IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley & Sons, Ltd.